Get the Stockscreener App
46.06
2.39%
-1.13
After Hours:
45.98
-0.08
-0.17%
Moderna Inc stock is traded at $46.06, with a volume of 6.17M.
It is down -2.39% in the last 24 hours and up +1.52% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$47.19
Open:
$47.07
24h Volume:
6.17M
Relative Volume:
0.84
Market Cap:
$18.28B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-5.6542
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
-1.75%
1M Performance:
+1.52%
6M Performance:
+90.65%
1Y Performance:
+73.42%
1-Day Range:
$44.20
$47.07
1-Week Range:
$44.20
$49.26
52-Week Range:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
46.06 | 18.72B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
600.66 | 64.45B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
836.09 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.63 | 40.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
163.68 | 33.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Tells Fed. Circ. US Must Face COVID Vax Patent Case - Law360
Moderna and other groups get $60 million to develop Ebola vaccine - Reuters
Moderna (MRNA) and Merck (MRK) Report Promising Results for Canc - GuruFocus
Moderna gets $50M investment for Ebola vaccine candidate - Yahoo
Moderna and other groups get US$60 million to develop Ebola vaccine - CP24
Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls - Benzinga
Cambridge drugmaker Moderna joins the Ebola vaccine race - NBC Boston
Moderna joins race for Ebola vaccine as Bundibugyo strain spreads in Africa - The Business Journals
Moderna and CEPI expand collab to include Bundibugyo ebolavirus vaccine - The Pharma Letter
Moderna partners with CEPI on Ebola vaccine efforts amid outbreak in Africa - BioSpace
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting - ACCESS Newswire
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus - Investing News Network
Moderna Joins Global Initiative to Advance Vaccine Candidate for Bundibugyo Ebola Virus (MRNA) - Yahoo Finance
Moderna receives $50 million from CEPI for Bundibugyo Ebola vaccine - StreetInsider
Moderna (MRNA) Expands Vaccine Collaboration to Combat Bundibugy - GuruFocus
Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine - Yahoo! Finance Canada
Moderna, Inc. $MRNA Position Reduced by Legal & General Group Plc - MarketBeat
Moderna backs new Ebola vaccine as CEPI commits up to $50M - Stock Titan
MRNA Stock Quote Price and Forecast - CNN
Moderna Inc. stock (US60770K1034): routine insider RSU vesting activity highlights ongoing equity in - AD HOC NEWS
Anterix Stock Is Up 140%. Here's Why One Investor Just Bought $15.8 Million - The Motley Fool
Moderna (MRNA) CFO vests RSUs and withholds 533 shares to cover taxes - Stock Titan
Moderna (MRNA) Chief Legal Officer reports RSU vesting and tax-share withholdings - Stock Titan
Moderna (MRNA) president logs RSU vesting and tax-withholding share dispositions - Stock Titan
Moderna's revenues see strong international momentum in Q1 earnings - MSN
Jefferies Financial Group Inc. Sells 49,596 Shares of Moderna, Inc. $MRNA - MarketBeat
FDA panel backs XFG strain for 2026-27 COVID vaccine update (MRNA:NASDAQ) - Seeking Alpha
MRNA Stock Price, Quote & Chart | MODERNA INC (NASDAQ:MRNA) - ChartMill
WITTENBERG INVESTMENT MANAGEMENT, INC.'s Moderna Inc(MRNA) Holding History - GuruFocus
FDA’s VRBPAC faces complex COVID-19 landscape - BioWorld News
Moderna Inc at Bernstein Strategic Decisions Conference Transcript - GuruFocus
Moderna is prepared to supply recommended COVID vaccine composition for 2026-27 season by mid-August: briefing docs - marketscreener.com
The Escalator: Moderna, Spectrum Science, Supreme Group and more - Medical Marketing and Media
FDA advisers recommend COVID vaccines be updated to target current dominant variant - marketscreener.com
Moderna Stock Price — MRNA Chart - TradingView
Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds - BioSpace
Key facts: Moderna Readies 2026–27 XFG Booster; FDA Advisers to Vote - TradingView
FDA AdCom panel to review and vote on next COVID shots - Seeking Alpha
US FDA advisers to weigh updating 2026-27 COVID vaccines for XFG variant - marketscreener.com
UBS reiterates Moderna stock rating on melanoma trial catalyst - Investing.com
UBS reiterates Moderna stock rating on melanoma trial catalyst By Investing.com - Investing.com Canada
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine - Yahoo Finance
Moderna Inc. stock (US60770K1034): Vaccine player back in focus after infectious disease headline - AD HOC NEWS
Moderna, Inc. (MRNA) Stock Analysis: Navigating a Biotech Giant with a 260% Revenue Growth - DirectorsTalk Interviews
Moderna stock (US60770K1034): mRNA specialist in focus after latest quarterly figures - AD HOC NEWS
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Britannica
Moderna Inc. (NASDAQ: MRNA) Stock Under Pressure as mRNA Platform Seeks New Applications - foreignpolicyjournal.com
Moderna director Noubar Afeyan sells $433,878 in stock By Investing.com - Investing.com Australia
Insider Selling: Moderna (NASDAQ:MRNA) Director Sells $433,878.92 in Stock - MarketBeat
Moderna director Noubar Afeyan sells $433,878 in stock - Investing.com
Flagship Pioneering trades 9,263 Moderna (MRNA) shares via option exercise - Stock Titan
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.00%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):